Art. 31 Directive (EU) 2001/83

In forcesince 16 Nov 2012cited 33×
1.

The Member States, the Commission, the applicant or the marketing authorisation holder shall, in specific cases where the interests of the Union are involved, refer the matter to the Committee for application of the procedure laid down in Articles 32, 33 and 34 before any decision is reached on an application for a marketing authorisation or on the suspension or revocation of a marketing authorisation, or on any other variation of the marketing authorisation which appears necessary.

Where the referral results from the evaluation of data relating to pharmacovigilance of an authorised medicinal product, the matter shall be referred to the Pharmacovigilance Risk Assessment Committee and Article 107j(2) may be applied. The Pharmacovigilance Risk Assessment Committee shall issue a recommendation according to the procedure laid down in Article 32. The final recommendation shall be forwarded to the Committee for Medicinal Products for Human Use or to the coordination group, as appropriate, and the procedure laid down in Article 107k shall apply.

However, where one of the criteria listed in Article 107i(1) is met, the procedure laid down in Articles 107i to 107k shall apply.

The Member State concerned or the Commission shall clearly identify the question which is referred to the Committee for consideration and shall inform the applicant or the marketing authorisation holder.

The Member States and the applicant or the marketing authorisation holder shall supply the Committee with all available information relating to the matter in question.

2.

Where the referral to the Committee concerns a range of medicinal products or a therapeutic class, the Agency may limit the procedure to certain specific parts of the authorisation.

In that event, Article 35 shall apply to those medicinal products only if they were covered by the authorisation procedures referred to in this Chapter.

Where the scope of the procedure initiated under this Article concerns a range of medicinal products or a therapeutic class, medicinal products authorised in accordance with Regulation (EC) No 726/2004 which belong to that range or class shall also be included in the procedure.

3.

Without prejudice to paragraph 1, a Member State may, where urgent action is necessary to protect public health at any stage of the procedure, suspend the marketing authorisation and prohibit the use of the medicinal product concerned on its territory until a definitive decision is adopted. It shall inform the Commission, the Agency and the other Member States, no later than the following working day, of the reasons for its action.

4.

Where the scope of the procedure initiated under this Article, as determined in accordance with paragraph 2, includes medicinal products authorised in accordance with Regulation (EC) No 726/2004, the Commission may, where urgent action is necessary to protect public health, at any stage of the procedure, suspend the marketing authorisations and prohibit the use of the medicinal products concerned until a definitive decision is adopted. The Commission shall inform the Agency and the Member States no later than the following working day of the reasons for its action.

The 10 that are cited most themselves, of 33.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…20Law

    … 107j odst. 2 směrnice 2001/83/ES. 9. Odchylně od odstavců 1 až 7 tohoto článku, pokud se postup podle článků 31 nebo 107i až 107k směrnice 2001/83/ES týká skupiny léčivých přípravků nebo terapeutické skupiny, vztahuje …

  • Directive (EU) 2004/27Lawamends

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    … Januar 2013 über die Zulassungen für Humanarzneimittel mit dem Wirkstoff „Tolperison“ gemäß Artikel 31 der Richtlinie 2001/83/EG des Europäischen Parlaments und des Rates erlässt DAS GERICHT (Fünfte Kammer) unter Mitwirkung des …

    11 Dec 2014 · 62013TJ0189

  • Arrêt de la Cour (huitième chambre) du 3 décembre 2015. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    Par son pourvoi, PP Nature-Balance Lizenz GmbH (ci-après «Nature-Balance») demande l’annulation de l’arrêt du Tribunal de l’Union européenne du 11 décembre 2014, PP Nature-Balance Lizenz/Commission (T‑189/13, EU:T:2014:1056, …

    3 Dec 2015 · 62015CJ0082

  • Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecision

    In the course of those proceedings, the H igh Court of Justice of England and Wales, Queen’s Bench Division (Administrative Court) decided to stay the proceedings and refer the following questions to the Court for a preliminary …

    16 Oct 2008 · 62006CJ0452

  • Judgment of the General Court (Fourth Chamber) of 19 September 2019. GE Healthcare A/S v European Commission.Decision

    In any event, the Commission rightly points out that when questions which are relevant to the EU are brought before a committee, such as the PRAC or the CHMP, in the context of the procedure set out in Article 31(1) of Directive 2001/83, …

    19 Sep 2019 · 62017TJ0783

  • Arrêt du Tribunal (cinquième chambre) du 20 octobre 2016. Dr. August Wolff GmbH & Co. KG Arzneimittel et Remedia d.o.o. contre Commission euDecision

    URTEIL DES GERICHTS (Fünfte Kammer) 20. Oktober 2016( * ) „Humanarzneimittel – Art. 31 der Richtlinie 2001/83/EG – Art. 116 der Richtlinie 2001/83 – Wirkstoff Estradiol – Beschluss der Kommission, mit dem gegenüber den …

    20 Oct 2016 · 62014TJ0672

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    The EMA relies on the principle of mutual recognition and argues that it is not possible for a regulatory authority, such as the Commission or itself, to revise the assessment of another regulatory authority in the context of the …

    5 May 2021 · 62018TJ0611

  • Order of the President of the General Court of 19 August 2019. BASF AS v European Commission.Decision

    … to suspend the operation of the Commission Implementing Decision of 6 June 2019 concerning, in the framework of Article 31 of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations of medicinal …

    19 Aug 2019 · 62019TO0472

  • Judgment of the Court of First Instance (Fifth Chamber) of 31 January 2006. Merck Sharp & Dohme Ltd and Others v Commission of the European Decision

    Chapter 4 (‘Mutual recognition of authorisations’) of Title III HUM (‘Placing on the market’) contains the following provisions: ‘Article 27 [corresponding to Article 8 of Directive 75/319, as amended]: In order to facilitate the …

    31 Jan 2006 · 62003TJ0273